Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Opat

Showing results (51-60 of 133) with videos related to

Pageof 14
Sort By:
Neuro-Oncology|March 19, 2013
Rituximab is associated with improved survival for aggressive B cell CNS lymphomaGareth Gregory, Ashwini Arumugaswamy, Teresa Leung, et al.
Internal Medicine Journal|November 27, 2022
Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2Briony Shaw, Jake Shortt, Michael Low, et al.
Internal Medicine Journal|July 2, 2020
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experienceAditya Tedjaseputra, Michael Gilbertson, Michael Low, et al.
Ejhaem|August 21, 2025
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B-Cell Lymphoma From Diagnosis to Transformation at RelapseMark Waltham, Jonathan Wong, Galina Polekhina, et al.
Leukemia & Lymphoma|November 24, 2022
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient ProgramStephen P Mulligan, Stephen Opat, Chan Y Cheah, et al.
Leukemia & Lymphoma|September 28, 2020
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapyMaciej Tatarczuch, Erin Paul, Michael Gilberston, et al.
British Journal of Haematology|October 2, 2014
The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemiaAshish Banerjee, Nicole A Mifsud, Robert Bird, et al.
Blood Advances|January 27, 2022
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNAAlex F Herrera, Samuel Tracy, Brandon Croft, et al.
Journal of Clinical Medicine|October 29, 2025
Development and Validation of Prognostic Models for Treatment Response of Patients with B-Cell Lymphoma: Standard Statistical and Machine-Learning ApproachesAdugnaw Zeleke Alem, Itismita Mohanty, Nalini Pati, et al.
Research and Practice in Thrombosis and Haemostasis|September 1, 2020
Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapyHiu Lam Agnes Yuen, Alison Slocombe, Vanessa Heron, et al.
Pageof 14

Showing results (51-60 of 133) with videos related to

Sort By:
Pageof 14
Neuro-Oncology|March 19, 2013
Rituximab is associated with improved survival for aggressive B cell CNS lymphomaGareth Gregory, Ashwini Arumugaswamy, Teresa Leung, et al.
Internal Medicine Journal|November 27, 2022
Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2Briony Shaw, Jake Shortt, Michael Low, et al.
Internal Medicine Journal|July 2, 2020
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experienceAditya Tedjaseputra, Michael Gilbertson, Michael Low, et al.
Ejhaem|August 21, 2025
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B-Cell Lymphoma From Diagnosis to Transformation at RelapseMark Waltham, Jonathan Wong, Galina Polekhina, et al.
Leukemia & Lymphoma|November 24, 2022
Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient ProgramStephen P Mulligan, Stephen Opat, Chan Y Cheah, et al.
Leukemia & Lymphoma|September 28, 2020
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapyMaciej Tatarczuch, Erin Paul, Michael Gilberston, et al.
British Journal of Haematology|October 2, 2014
The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemiaAshish Banerjee, Nicole A Mifsud, Robert Bird, et al.
Blood Advances|January 27, 2022
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNAAlex F Herrera, Samuel Tracy, Brandon Croft, et al.
Journal of Clinical Medicine|October 29, 2025
Development and Validation of Prognostic Models for Treatment Response of Patients with B-Cell Lymphoma: Standard Statistical and Machine-Learning ApproachesAdugnaw Zeleke Alem, Itismita Mohanty, Nalini Pati, et al.
Research and Practice in Thrombosis and Haemostasis|September 1, 2020
Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapyHiu Lam Agnes Yuen, Alison Slocombe, Vanessa Heron, et al.
Pageof 14